Which has preferable valuation and earnings, SVA or INBX?

Sinovac Biotech has higher revenue and earnings than Inhibrx Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A Inhibrx Biosciences $1.30M 1,098.23 -$140.05M -$8.88 N/A

Is SVA or INBX more profitable?

Sinovac Biotech's return on equity of 0.00% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Sinovac Biotech N/A N/A N/A Inhibrx Biosciences N/A -563.90% -83.48%

Which has better valuation & earnings, SVA or OMER?

Omeros has lower revenue, but higher earnings than Sinovac Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A Omeros N/A N/A -$3.35M $1.28 14.54

Is SVA or OMER more profitable?

Sinovac Biotech's return on equity of 0.00% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Sinovac Biotech N/A N/A N/A Omeros N/A -164.92% 69.41%

Which has higher valuation & earnings, KLRA or SVA?

Sinovac Biotech has higher revenue and earnings than Kailera Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kailera Therapeutics N/A N/A -$148.96M -$3.65 thousand N/A Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A

Is KLRA or SVA more profitable?

Company Net Margins Return on Equity Return on Assets Kailera Therapeutics N/A N/A N/A Sinovac Biotech N/A N/A N/A

Which has stronger earnings & valuation, MAZE or SVA?

Sinovac Biotech has higher revenue and earnings than Maze Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maze Therapeutics $167.50M 8.77 -$131.12M -$2.52 N/A Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A

Is MAZE or SVA more profitable?

Sinovac Biotech's return on equity of 0.00% beat Maze Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Maze Therapeutics N/A -34.94% -30.18% Sinovac Biotech N/A N/A N/A

Which has better earnings and valuation, AVBP or SVA?

Sinovac Biotech has higher revenue and earnings than ArriVent BioPharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ArriVent BioPharma N/A N/A -$166.31M -$3.62 N/A Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A

Is AVBP or SVA more profitable?

Sinovac Biotech's return on equity of 0.00% beat ArriVent BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets ArriVent BioPharma N/A -50.26% -46.66% Sinovac Biotech N/A N/A N/A

Sinovac Biotech (SVA) Competitors

$6.47 0.00 (0.00%)

As of 10/2/2026

Compare

SVA vs. INBX, OMER, KLRA, MAZE, and AVBP

Should you buy Sinovac Biotech stock or one of its competitors? Sinovac Biotech's main competitors and comparable companies include Inhibrx Biosciences (INBX), Omeros (OMER), Kailera Therapeutics (KLRA), Maze Therapeutics (MAZE), and ArriVent BioPharma (AVBP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Sinovac Biotech compare to Inhibrx Biosciences?

Sinovac Biotech (NASDAQ:SVA) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

Sinovac Biotech currently has a consensus price target of $1.00, suggesting a potential downside of 84.54%. Inhibrx Biosciences has a consensus price target of $197.50, suggesting a potential upside of 103.63%. Given Inhibrx Biosciences' higher possible upside, analysts clearly believe Inhibrx Biosciences is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Inhibrx Biosciences	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

Sinovac Biotech has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.81, meaning that its share price is 281% more volatile than the broader market.

82.5% of Inhibrx Biosciences shares are held by institutional investors. 12.8% of Sinovac Biotech shares are held by company insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Sinovac Biotech's return on equity of 0.00% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sinovac Biotech	N/A	N/A	N/A
Inhibrx Biosciences	N/A	-563.90%	-83.48%

Sinovac Biotech has higher revenue and earnings than Inhibrx Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A
Inhibrx Biosciences	$1.30M	1,098.23	-$140.05M	-$8.88	N/A

In the previous week, Inhibrx Biosciences had 11 more articles in the media than Sinovac Biotech. MarketBeat recorded 11 mentions for Inhibrx Biosciences and 0 mentions for Sinovac Biotech. Inhibrx Biosciences' average media sentiment score of 0.98 beat Sinovac Biotech's score of 0.00 indicating that Inhibrx Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Sinovac Biotech	Neutral
Inhibrx Biosciences	Positive

Summary

Inhibrx Biosciences beats Sinovac Biotech on 9 of the 14 factors compared between the two stocks.

How does Sinovac Biotech compare to Omeros?

Sinovac Biotech (NASDAQ:SVA) and Omeros (NASDAQ:OMER) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

Omeros has lower revenue, but higher earnings than Sinovac Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A
Omeros	N/A	N/A	-$3.35M	$1.28	14.54

Sinovac Biotech's return on equity of 0.00% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sinovac Biotech	N/A	N/A	N/A
Omeros	N/A	-164.92%	69.41%

In the previous week, Omeros had 3 more articles in the media than Sinovac Biotech. MarketBeat recorded 3 mentions for Omeros and 0 mentions for Sinovac Biotech. Omeros' average media sentiment score of 0.67 beat Sinovac Biotech's score of 0.00 indicating that Omeros is being referred to more favorably in the news media.

Company	Overall Sentiment
Sinovac Biotech	Neutral
Omeros	Positive

Sinovac Biotech currently has a consensus price target of $1.00, indicating a potential downside of 84.54%. Omeros has a consensus price target of $34.00, indicating a potential upside of 82.70%. Given Omeros' higher possible upside, analysts clearly believe Omeros is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Omeros	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71

Sinovac Biotech has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, Omeros has a beta of 2.57, indicating that its share price is 157% more volatile than the broader market.

48.8% of Omeros shares are owned by institutional investors. 12.8% of Sinovac Biotech shares are owned by company insiders. Comparatively, 10.5% of Omeros shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Omeros beats Sinovac Biotech on 9 of the 13 factors compared between the two stocks.

How does Sinovac Biotech compare to Kailera Therapeutics?

Kailera Therapeutics (NASDAQ:KLRA) and Sinovac Biotech (NASDAQ:SVA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

Company	Net Margins	Return on Equity	Return on Assets
Kailera Therapeutics	N/A	N/A	N/A
Sinovac Biotech	N/A	N/A	N/A

Kailera Therapeutics presently has a consensus price target of $42.75, suggesting a potential upside of 311.45%. Sinovac Biotech has a consensus price target of $1.00, suggesting a potential downside of 84.54%. Given Kailera Therapeutics' higher possible upside, research analysts plainly believe Kailera Therapeutics is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kailera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Kailera Therapeutics had 9 more articles in the media than Sinovac Biotech. MarketBeat recorded 9 mentions for Kailera Therapeutics and 0 mentions for Sinovac Biotech. Kailera Therapeutics' average media sentiment score of 0.48 beat Sinovac Biotech's score of 0.00 indicating that Kailera Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Kailera Therapeutics	Neutral
Sinovac Biotech	Neutral

Sinovac Biotech has higher revenue and earnings than Kailera Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kailera Therapeutics	N/A	N/A	-$148.96M	-$3.65 thousand	N/A
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A

Summary

Kailera Therapeutics beats Sinovac Biotech on 5 of the 8 factors compared between the two stocks.

How does Sinovac Biotech compare to Maze Therapeutics?

Maze Therapeutics (NASDAQ:MAZE) and Sinovac Biotech (NASDAQ:SVA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

Maze Therapeutics has a beta of 2.16, meaning that its share price is 116% more volatile than the broader market. Comparatively, Sinovac Biotech has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market.

Sinovac Biotech's return on equity of 0.00% beat Maze Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-34.94%	-30.18%
Sinovac Biotech	N/A	N/A	N/A

In the previous week, Maze Therapeutics had 12 more articles in the media than Sinovac Biotech. MarketBeat recorded 12 mentions for Maze Therapeutics and 0 mentions for Sinovac Biotech. Maze Therapeutics' average media sentiment score of 0.57 beat Sinovac Biotech's score of 0.00 indicating that Maze Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Maze Therapeutics	Positive
Sinovac Biotech	Neutral

Sinovac Biotech has higher revenue and earnings than Maze Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$167.50M	8.77	-$131.12M	-$2.52	N/A
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A

Maze Therapeutics presently has a consensus price target of $63.40, suggesting a potential upside of 139.88%. Sinovac Biotech has a consensus price target of $1.00, suggesting a potential downside of 84.54%. Given Maze Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Maze Therapeutics is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.08
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Maze Therapeutics beats Sinovac Biotech on 8 of the 12 factors compared between the two stocks.

How does Sinovac Biotech compare to ArriVent BioPharma?

ArriVent BioPharma (NASDAQ:AVBP) and Sinovac Biotech (NASDAQ:SVA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

ArriVent BioPharma presently has a consensus target price of $44.86, suggesting a potential upside of 58.67%. Sinovac Biotech has a consensus target price of $1.00, suggesting a potential downside of 84.54%. Given ArriVent BioPharma's higher possible upside, equities analysts clearly believe ArriVent BioPharma is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

ArriVent BioPharma has a beta of 1.34, meaning that its stock price is 34% more volatile than the broader market. Comparatively, Sinovac Biotech has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

Sinovac Biotech has higher revenue and earnings than ArriVent BioPharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.62	N/A
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A

Sinovac Biotech's return on equity of 0.00% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-50.26%	-46.66%
Sinovac Biotech	N/A	N/A	N/A

In the previous week, ArriVent BioPharma had 1 more articles in the media than Sinovac Biotech. MarketBeat recorded 1 mentions for ArriVent BioPharma and 0 mentions for Sinovac Biotech. ArriVent BioPharma's average media sentiment score of 0.90 beat Sinovac Biotech's score of 0.00 indicating that ArriVent BioPharma is being referred to more favorably in the media.

Company	Overall Sentiment
ArriVent BioPharma	Positive
Sinovac Biotech	Neutral

9.5% of ArriVent BioPharma shares are held by institutional investors. 8.6% of ArriVent BioPharma shares are held by insiders. Comparatively, 12.8% of Sinovac Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

ArriVent BioPharma and Sinovac Biotech tied by winning 6 of the 12 factors compared between the two stocks.

Get Sinovac Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SVA vs. The Competition

Export

Metric	Sinovac Biotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$644.67M	$3.87B	$7.14B	$13.17B
Dividend Yield	N/A	3.64%	2.53%	16.78%
P/E Ratio	N/A	13.06	275.68	26.04
Price / Sales	1.67	1,374.07	658.29	101.16
Price / Cash	11.89	122.60	77.60	51.75
Price / Book	0.07	16.63	10.93	6.31
Net Income	-$59.68M	-$22.71M	$3.51B	$362.16M
7 Day Performance	N/A	-2.99%	-2.00%	-1.66%
1 Month Performance	N/A	-10.60%	-6.15%	-4.50%
1 Year Performance	N/A	19.44%	7.44%	2.06%

Sinovac Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SVA Sinovac Biotech	0.8641 of 5 stars	$6.47 flat	$1.00 -84.5%	N/A	$644.67M	$386.01M	N/A	2,602	High Trading Volume
INBX Inhibrx Biosciences	3.8978 of 5 stars	$100.10 -0.3%	$197.50 +97.3%	+176.6%	$1.47B	$1.30M	N/A	110	Positive News
OMER Omeros	3.9724 of 5 stars	$20.17 +0.2%	$34.00 +68.6%	+341.0%	$1.46B	N/A	15.76	175	News Coverage
KLRA Kailera Therapeutics	2.5666 of 5 stars	$11.26 -6.0%	$42.75 +279.7%	N/A	$1.46B	N/A	N/A	145	News Coverage
MAZE Maze Therapeutics	2.7002 of 5 stars	$25.93 -1.1%	$63.40 +144.5%	-0.3%	$1.44B	$167.50M	N/A	141	News Coverage Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SVA) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sinovac Biotech (SVA) Competitors

SVA vs. INBX, OMER, KLRA, MAZE, and AVBP

How does Sinovac Biotech compare to Inhibrx Biosciences?

Summary

How does Sinovac Biotech compare to Omeros?

Summary

How does Sinovac Biotech compare to Kailera Therapeutics?

Summary

How does Sinovac Biotech compare to Maze Therapeutics?

Summary

How does Sinovac Biotech compare to ArriVent BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVA vs. The Competition

Sinovac Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sinovac Biotech (SVA) Competitors

SVA vs. INBX, OMER, KLRA, MAZE, and AVBP

How does Sinovac Biotech compare to Inhibrx Biosciences?

Do analysts prefer SVA or INBX?

Which has more risk & volatility, SVA or INBX?

Do insiders and institutionals believe in SVA or INBX?

Is SVA or INBX more profitable?

Which has preferable valuation and earnings, SVA or INBX?

Does the media favor SVA or INBX?

Summary

How does Sinovac Biotech compare to Omeros?

Which has better valuation & earnings, SVA or OMER?

Is SVA or OMER more profitable?

Does the media favor SVA or OMER?

Do analysts recommend SVA or OMER?

Which has more volatility & risk, SVA or OMER?

Do institutionals & insiders have more ownership in SVA or OMER?

Summary

How does Sinovac Biotech compare to Kailera Therapeutics?

Is KLRA or SVA more profitable?

Do analysts recommend KLRA or SVA?

Does the media favor KLRA or SVA?

Which has higher valuation & earnings, KLRA or SVA?

Summary

How does Sinovac Biotech compare to Maze Therapeutics?

Which has more risk & volatility, MAZE or SVA?

Is MAZE or SVA more profitable?

Does the media favor MAZE or SVA?

Which has stronger earnings & valuation, MAZE or SVA?

Do analysts prefer MAZE or SVA?

Summary

How does Sinovac Biotech compare to ArriVent BioPharma?

Do analysts rate AVBP or SVA?

Which has more risk and volatility, AVBP or SVA?

Which has better earnings and valuation, AVBP or SVA?

Is AVBP or SVA more profitable?

Does the media refer more to AVBP or SVA?

Do insiders and institutionals hold more shares of AVBP or SVA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVA vs. The Competition

Sinovac Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools